Drugs Xagena
Significant liver injury associated with the use of Tolvaptan ( Samsca ) has been reported. In a large double-blind, 3-year, placebo-controlled trial ( TEMPO 3:4 ) in about 1400 patients with autosoma ...
Drug-induced liver injury has been observed in clinical trials investigating potential use in patients with autosomal dominant polycystic kidney disease ( ADPKD, an unlicensed indication ) at higher d ...
Hyponatremia ( serum sodium concentration, less than 135 mmol per liter ) is a predictor of death among patients with chronic heart failure and cirrhosis. At present, therapy for acute and chronic hyp ...
Tolvaptan ( Samsca ) is an orally administered, nonpeptide, selective arginine vasopressin V(2) receptor antagonist that increases free water clearance, thereby correcting low serum sodium levels. ...
